Evidence map›Paper›PMID 42467304›Full record

ArticleJournal of cancer research and clinical oncology2026

The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer.

M Weich, L Christl, M Kiesel, J Salmen, A Wöckel, J Diessner, E Gerhard-Hartmann, T Schlaiss

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M WeichDepartment of Gynaecology and Obstetrics, University of Würzburg, Josef-Schneider-Str. 4, 97080, Würzburg, Germany.
L ChristlInstitute of Pathology, University of Würzburg, Versbacher Str. 3, 97078, Würzburg, Germany.
M KieselDepartment of Gynaecology and Obstetrics, University of Würzburg, Josef-Schneider-Str. 4, 97080, Würzburg, Germany.
J SalmenDepartment of Gynaecology and Obstetrics, University of Würzburg, Josef-Schneider-Str. 4, 97080, Würzburg, Germany.
A WöckelDepartment of Gynaecology and Obstetrics, University of Würzburg, Josef-Schneider-Str. 4, 97080, Würzburg, Germany.
J DiessnerDepartment of Gynaecology and Obstetrics, University of Würzburg, Josef-Schneider-Str. 4, 97080, Würzburg, Germany.
E Gerhard-Hartmann *Institute of Pathology, University of Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany.
T Schlaiss *Department of Gynaecology and Obstetrics, University of Würzburg, Josef-Schneider-Str. 4, 97080, Würzburg, Germany. Schlaiss_T@ukw.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe antibody-drug conjugates (ADCs) sacituzumab govitecan (SG) and datopotamab deruxtecan target trophoblast cell surface antigen 2 (TROP-2) and have shown significant efficacy in HER2-negative metastatic breast cancer (mBC). As TROP-2 may serve as a target across multiple treatment lines, detailed information on TROP-2 expression over time is of great interest.

methodsTROP-2 expression was analyzed in breast cancer (BC) samples from patients treated at the University Hospital Würzburg between 2004 and 2025 at clinically indicated biopsy time points (TP), and, in a subset, before and after SG treatment. Expression was assessed immunohistochemically using the H-score (range 0-300).

resultsWe evaluated 229 samples from 76 patients. Overall, patient-level TROP-2 expression was high (mean H-score 241.3 ± 73.2) and largely stable over time (TP1: 235.7 ± 60.8, n = 76; TP2: 244.6 ± 77.4, n = 72; TP3: 245.3 ± 84.4, n = 39; TP4: 244.9 ± 95.6, n = 8). However, 21 patients exhibited a decline in TROP-2 expression during disease progression, defined as a decrease of ≥ 50 H-score points between two consecutive TPs. Among 13 patients with paired biopsies obtained pre- and post-SG treatment, the mean TROP-2 H-score decreased from 227.0 ± 74.6 before SG to 202.9 ± 99.4 after SG (mean change - 24.1 ± 86.0; median 1.7, range - 170 to 110; Wilcoxon p = 0.542). TROP-2 H-score decreased in 6/13 patients and increased in 7/13 patients. Exploratory PFS analysis showed no statistically significant difference by post-SG TROP-2 change (log-rank p = 0.526).

conclusionTROP-2 expression was generally high and relatively stable; however, some patients showed declining levels over time.

Indexed as

Antigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCell Adhesion MoleculesAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedCamptothecinFemaleHumansImmunoconjugatesImmunohistochemistryMiddle AgedAntibodies, Monoclonal, HumanizedAntigens, NeoplasmBiomarkers, TumorCamptothecinCell Adhesion MoleculesImmunoconjugatessacituzumab govitecanTACSTD2 protein, humanBreast cancerH-scoreLongitudinal TROP-2 expressionSacituzumab govitecanTROP-2

Identifiers

PMID42467304
PMCPMC13379550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.